<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Miluzio A</submitter><funding>Associazione Italiana per la Ricerca sul Cancro</funding><funding>Fondazione Romeo ed Enrica Invernizzi</funding><pagination>104390</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9795807</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>87</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The COVID-19 pandemic is an infectious disease caused by SARS-CoV-2. The first step of SARS-CoV-2 infection is the recognition of angiotensin-converting enzyme 2 (ACE2) receptors by the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein. Although the molecular and structural bases of the SARS-CoV-2-RBD/hACE2 interaction have been thoroughly investigated in vitro, the relationship between hACE2 expression and in vivo infection is less understood.&lt;h4>Methods&lt;/h4>Here, we developed an efficient SARS-CoV-2-RBD binding assay suitable for super resolution microscopy and simultaneous hACE2 immunodetection and mapped the correlation between hACE2 receptor abundance and SARS-CoV-2-RBD binding, both in vitro and in human lung biopsies. Next, we explored the specific</pubmed_abstract><journal>EBioMedicine</journal><pubmed_title>Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2.</pubmed_title><pmcid>PMC9795807</pmcid><funding_grant_id>26178</funding_grant_id><pubmed_authors>Scagliola A</pubmed_authors><pubmed_authors>Oliveto S</pubmed_authors><pubmed_authors>Manfrini N</pubmed_authors><pubmed_authors>Pesce E</pubmed_authors><pubmed_authors>Conti M</pubmed_authors><pubmed_authors>Manganaro L</pubmed_authors><pubmed_authors>Ricciardi S</pubmed_authors><pubmed_authors>Biffo S</pubmed_authors><pubmed_authors>Cordiglieri C</pubmed_authors><pubmed_authors>Abrignani S</pubmed_authors><pubmed_authors>Fasciani A</pubmed_authors><pubmed_authors>Terracciano L</pubmed_authors><pubmed_authors>De Francesco R</pubmed_authors><pubmed_authors>Cuomo A</pubmed_authors><pubmed_authors>Toccafondi M</pubmed_authors><pubmed_authors>Donnici L</pubmed_authors><pubmed_authors>Grifantini R</pubmed_authors><pubmed_authors>Bombaci M</pubmed_authors><pubmed_authors>Miluzio A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2.</name><description>&lt;h4>Background&lt;/h4>The COVID-19 pandemic is an infectious disease caused by SARS-CoV-2. The first step of SARS-CoV-2 infection is the recognition of angiotensin-converting enzyme 2 (ACE2) receptors by the receptor-binding domain (RBD) of the viral Spike (S) glycoprotein. Although the molecular and structural bases of the SARS-CoV-2-RBD/hACE2 interaction have been thoroughly investigated in vitro, the relationship between hACE2 expression and in vivo infection is less understood.&lt;h4>Methods&lt;/h4>Here, we developed an efficient SARS-CoV-2-RBD binding assay suitable for super resolution microscopy and simultaneous hACE2 immunodetection and mapped the correlation between hACE2 receptor abundance and SARS-CoV-2-RBD binding, both in vitro and in human lung biopsies. Next, we explored the specific</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-29T04:35:47.715Z</modification><creation>2024-12-04T03:30:31.375Z</creation></dates><accession>S-EPMC9795807</accession><cross_references><pubmed>36584595</pubmed><doi>10.1016/j.ebiom.2022.104390</doi></cross_references></HashMap>